Anavex Life Sciences Corp (AVXL)
Sector • Healthcare Industry • Biotechnology & Pharmaceuticals |
Industry • Biotechnology & Pharmaceuticals |
Sector • Healthcare |
News
ANAVEX3-71: Promising Potential for Schizophrenia Treatment Enters U.S. Phase 2 Clinical Trial
The Awakening Progress on Rett Syndrome: An Unpacking of Anavex Life Sciences* Breakthrough
Unlocking the Potential: ANAVEX2-73*s Remarkable Impact on Gene Pathways for Rett Syndrome
Anavex Life Sciences Corp*s EPS Soars by 454.76% Despite Decline in Revenue during Q4 2023
Top-line and margins have crumbled at in the fourth quarter of 2022 earnings season
Top-line and bottom-line have crumbled at in the fiscal time-frame ending September 30 2022
The Deficit has intensified more at AVXL over the financial interval closing September 30 2018